United States Tumor Profiling Market Size and Forecast 2025–2033

The United States Tumor Profiling Market is entering a transformative era where technology, oncology research, and precision medicine are converging to redefine cancer care. According to Renub Research, the market is expected to reach US$ 7.44 billion by 2033, up from US$ 3.41 billion in 2024, growing at a CAGR of 9.05% from 2025 to 2033. This rapidly expanding sector is being propelled by advanced genomic technologies, the rising burden of cancer across the country, and the accelerating demand for personalized treatment.

As oncologists shift from generalized treatment plans to targeted, data-driven approaches, tumor profiling is increasingly becoming a foundational pillar in modern clinical practice. With innovations such as next-generation sequencing (NGS), mass spectrometry, proteomics, and AI-driven analytics, the United States is cementing its position as one of the global leaders in precision oncology.

United States Tumor Profiling Industry Overview

The U.S. tumor profiling landscape has evolved dramatically over the last decade. Oncologists today rely heavily on genomic, proteomic, epigenetic, and metabolomic insights to tailor treatment plans for individual patients. Tumor profiling enables clinicians to map mutations, biomarkers, and molecular pathways that drive cancer progression—unlocking a new era of customized therapy selection, improved treatment outcomes, and fewer unnecessary side effects.

With cancer remaining one of the leading causes of death in the United States, the adoption of tumor profiling has surged. The American Cancer Society projects more than 2,041,910 new cancer cases in 2025, strengthening the need for precision diagnostic tools. Strong R&D infrastructure, advanced healthcare systems, and growing investment in oncology research have ensured the United States remains at the forefront of this market.

A collaborative ecosystem—where pharmaceutical companies, diagnostic laboratories, biotech firms, and academic institutions work closely together—continues to drive innovation. These efforts enhance biomarker discovery, accelerate clinical trials, and support the commercialization of next-generation profiling technologies.

Despite this growth, challenges remain. Tumor profiling technologies are expensive, data interpretation is complex, and accessibility varies greatly across regions. Nonetheless, as reimbursement policies evolve and technology becomes more cost-efficient, adoption is expected to rise steadily.

Key Factors Driving Growth in the U.S. Tumor Profiling Market

1. Rising Cancer Prevalence & the Surge in Precision Medicine

The increasing number of cancer diagnoses in the United States is a primary catalyst for tumor profiling adoption. Precision medicine—where treatment is tailored to a patient’s unique tumor biology—has become the new standard in oncology. Tumor profiling identifies mutations, biomarkers, signaling pathways, and therapeutic targets, enabling oncologists to select the most effective treatments.

This personalized approach:

Improves survival outcomes

Reduces adverse effects

Helps avoid ineffective therapies

Enhances monitoring of disease progression

Patients, healthcare systems, and insurers alike recognize the value and cost efficiency of early, data-driven decision-making. As awareness of personalized medicine’s benefits grows, demand for tumor profiling is expected to rise across hospitals, cancer centers, and research institutions.

2. Rapid Technological Advancements in Molecular Diagnostics

The U.S. market is home to world-leading innovations. Technologies such as:

Next-Generation Sequencing (NGS)

Mass Spectrometry

Immunohistochemistry (IHC)

Polymerase Chain Reaction (PCR)

In Situ Hybridization (ISH)

Microarray analysis

have significantly enhanced the accuracy and depth of tumor analysis.

The integration of AI and bioinformatics has become especially crucial, helping clinicians interpret complex datasets and identify actionable variants faster than ever. AI-driven analytics now assist with identifying rare mutations, predicting treatment response, and improving the standardization of results across institutions.

As sequencing costs continue to decline and automated platforms enter the market, tumor profiling is becoming more accessible, even to mid-sized laboratories and community healthcare networks.

3. Expanding Research Collaborations & Industry Investments

The United States remains a powerhouse in oncology research. Pharmaceutical giants, academic institutions, and diagnostic laboratories actively collaborate to:

Discover new biomarkers

Advance companion diagnostics

Enhance targeted therapy development

Improve multidimensional tumor profiling techniques

Government initiatives supporting precision oncology—such as the Cancer Moonshot—continue to fuel momentum across the industry. Investments in clinical trials, digital pathology, and advanced sequencing platforms are accelerating the creation of next-generation profiling tools.

These partnerships ensure tumor profiling shifts from research labs to frontline clinical practice swiftly and effectively.

Key Challenges in the U.S. Tumor Profiling Market

1. High Cost of Tumor Profiling & Limited Accessibility

The cost of advanced profiling tests remains a major barrier, especially for small hospitals and rural health systems. Factors such as equipment investments, skilled workforce requirements, and complex data analytics contribute to high overall operational costs.

Although reimbursement policies are gradually improving, inconsistent coverage still limits patient access. This creates disparities in precision oncology availability—particularly among underserved populations and regions.

Without adequate reimbursement, widespread adoption will continue to face hurdles.

2. Data Complexity & Interpretation Issues

Tumor profiling produces massive datasets that require expert-level interpretation through bioinformatics pipelines. Challenges include:

Variability in data quality

Lack of standardized reporting formats

Difficulty identifying clinically actionable findings

Interoperability issues between platforms

While artificial intelligence and machine learning are making strides, standardization across laboratories remains a pressing need. Misinterpretation risks can impact treatment decisions and patient outcomes, making data accuracy paramount.

United States Tumor Profiling Market: State-Level Analysis

Regional discrepancies in healthcare infrastructure, investment, and technology adoption shape the tumor profiling landscape across the country. Below is a state-by-state highlight of the top-performing markets.

California: The Innovation Capital for Tumor Profiling

California remains a dominant force in the U.S. tumor profiling market thanks to:

A thriving biotech ecosystem

Top-tier research institutions

Leading cancer centers

High investment in precision oncology

Statewide collaborations between pharmaceutical companies, diagnostic manufacturers, and academic hospitals continue to push the boundaries of genomic research.

California’s diverse population also provides robust clinical study data—fueling advancements in targeted biomarker research and clinical trials.

Texas: A Rapidly Expanding Oncology Powerhouse

Texas hosts several of the largest cancer care institutions in the nation and is rapidly adopting precision oncology systems. Increased infrastructure investments, collaborations with biotech companies, and an expanding patient pool are spurring growth.

The state’s active role in molecular diagnostics research, clinical trials, and precision medicine initiatives positions it as a major player in the southern United States.

New York: A Leader in Precision Diagnostics & Clinical Research

New York’s dense concentration of research universities, cancer institutes, and biotech firms makes it a key contributor to tumor profiling advancements.

The state leads in:

Clinical trial activity

Development of novel biomarkers

Adoption of AI-based molecular diagnostics

High-throughput sequencing capabilities

New York’s diverse demographics also support wide-scale studies across multiple cancer types.

Florida: Growing Demand Driven by an Aging Population

Florida has seen heightened adoption of tumor profiling due to its large senior population, which faces a higher incidence of cancer. Specialized cancer centers, research networks, and healthcare providers are rapidly integrating molecular diagnostics into treatment plans.

The state’s strategic partnerships with pharmaceutical companies and diagnostic labs further expand tumor profiling access in the southeastern U.S.

Recent Developments Shaping the Market

August 2024: The U.S. FDA approved Illumina's TruSight Oncology Comprehensive in vitro diagnostic (IVD) test.

This high-throughput genomic profiling panel analyzes over 500 genes, offering pan-cancer companion diagnostic claims and enabling rapid therapy matching.

Such approvals signal strong regulatory support for comprehensive genomic profiling, improving nationwide access to precision oncology tools.

Market Segmentation

By Technique

Genomics

Proteomics

Metabolomics

Epigenetics

By Technology

Immunoassays

Next-Generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

In Situ Hybridization

Microarrays

Mass Spectrometry

Others

By Application

Personalized Cancer Medicine

Oncological Diagnostics

Research

By States

California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, New Jersey, Washington, North Carolina, Massachusetts, Virginia, Michigan, Maryland, Colorado, Tennessee, Indiana, Arizona, Minnesota, Wisconsin, Missouri, Connecticut, South Carolina, Oregon, Louisiana, Alabama, Kentucky, Rest of United States.

Competitive Landscape: Key Players Covered

Each of the following companies plays a pivotal role through product innovation, partnerships, research, and commercialization:

Illumina Inc.

Qiagen N.V.

Exact Sciences Corporation

NeoGenomics Laboratories

Oxford Gene Technology IP Limited

Bruker Spatial Biology, Inc.

GenomeDX

Guardant Health

Profiles include company overview, key executives, revenue analysis, SWOT analysis, and recent developments.

Final Thoughts

The United States tumor profiling market stands at the forefront of a monumental shift in cancer care. As genomic science merges with AI-driven analytics, clinicians are increasingly equipped to deliver personalized, precisely targeted therapies that improve outcomes and reduce unnecessary treatments.

Despite cost barriers and data complexity challenges, the industry continues to push ahead with strong momentum. The focus on precision medicine, rising cancer prevalence, ongoing collaborations, and rapid technological advancement ensure that tumor profiling will remain a cornerstone of modern oncology through 2033 and beyond.

As America moves toward a future where every cancer patient receives tailored care based on their tumor’s unique molecular signature, the tumor profiling market’s growth trajectory appears not just promising—but inevitable.